{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464198476
| IUPAC_name = 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1''H''-purine-2,6-dione
| image = Pentoxifylline.svg
| width = 180
| image2 = Pentoxifylline xtal 2005 ball-and-stick.png
| width2 = 200

<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|p|ɛ|n|t|ɒ|k|ˈ|s|ɪ|f|ᵻ|l|iː|n|,_|-|ɪ|n}}
| tradename = Many names worldwide<ref name=generics/>
| Drugs.com = {{drugs.com|monograph|pentoxifylline}}
| MedlinePlus = a685027
| licence_US = Pentoxifylline
| pregnancy_AU = B1
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability = 10–30%<ref name = MSR>{{cite web|title=Trental, Pentoxil (pentoxifylline) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=3 February 2014|url=http://reference.medscape.com/drug/trental-pentoxil-pentoxifylline-342179#showall}}</ref>
| protein_bound =  
| metabolism = [[Hepatic]] and via [[erythrocytes]]
| elimination_half-life = 0.4–0.8 hours (1–1.6 hours for active metabolite)<ref name = MSR/> 
| excretion = Urine (95%), faeces (<4%)<ref name = MSR/>

<!--Identifiers-->
| IUPHAR_ligand = 7095
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 6493-05-6
| ATC_prefix = C04
| ATC_suffix = AD03
| PubChem = 4740
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00806
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4578
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SD6QCT3TSU
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00501
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 628
|synonyms=oxpentifylline (former [[Australian Approved Name|AAN]])<ref name = TGA>{{cite web|title=PRODUCT INFORMATION TRENTAL® 400|work=TGA eBusiness Services|publisher=sanofi-aventis australia pty limited|date=25 March 2010|accessdate=3 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06086-3|format=PDF}}</ref>
<!--Chemical data-->
| C=13 | H=18 | N=4 | O=3
| molecular_weight = 278.31 g/mol
| smiles = O=C2N(c1ncn(c1C(=O)N2CCCCC(=O)C)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BYPFEZZEUUWMEJ-UHFFFAOYSA-N
}}

'''Pentoxifylline''', also known as '''oxpentifylline''', is a xanthine derivative used as a drug to treat muscle pain in people with [[peripheral artery disease]].<ref name=Cochrane2012/> It is [[Generic drug|generic]] and sold under many brand names worldwide.<ref name=generics>Drugs.com [http://www.drugs.com/international/pentoxifylline.html drugs.com international listings for Pentoxifylline]. Page accessed Feb 1, 206</ref>

== Medical uses ==
Its primary use in medicine is to reduce pain, cramping, numbness, or weakness in the arms or legs which occurs due to [[intermittent claudication]], a form of muscle pain resulting from [[peripheral artery disease]]s.<ref name=Cochrane2012>{{cite journal |vauthors=Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA |title=Pentoxifylline for intermittent claudication |journal=The Cochrane Database of Systematic Reviews |volume=1 |issue= |pages=CD005262 |year=2012 |pmid=22258961 |doi=10.1002/14651858.CD005262.pub2 }}</ref> This is its only [[Food and Drug Administration|FDA]], [[Medicines and Healthcare Products Regulatory Agency|MHRA]] and [[Therapeutic Goods Administration|TGA]]-labelled indication.<ref name = TGA/><ref name = DM>{{cite web|title=PENTOXIFYLLINE tablet, extended release [Apotex Corp.]|work=DailyMed|publisher=Apotex Corp.|date=February 2013|accessdate=3 February 2014|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40ae2d9a-0d95-640d-0640-f76e7e1a13cb#nlm34067-9}}</ref><ref name = EMC>{{cite web|title=Trental 400 - Summary of Product Characteristics (SPC)|work=electronic Medicines Compendium|publisher=Sanofi|date=10 October 2013|accessdate=3 February 2014|url=http://www.medicines.org.uk/emc/medicine/338/SPC/Trental+400/}}</ref>

==Adverse effects==
Common side effects are belching, bloating, stomach discomfort or upset, nausea, vomiting, [[Dyspepsia|indigestion]], dizziness, and flushing.   Uncommon and rare side effects include angina, palpitations, hypersensitivity, [[Pruritus|itchiness]], rash,  [[Urticaria|hives]], bleeding, hallucinations, arrhythmias, and [[aseptic meningitis]].<ref name = MSR/><ref name = TGA/><ref name = DM/><ref name = EMC/>

Contraindications include intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral haemorrhage, and risk factors for haemorrhage.<ref name = MSR/>

== Mechanism ==
Like other methylated [[xanthine|xanthine derivatives]], pentoxifylline is a competitive nonselective [[phosphodiesterase inhibitor]]<ref name="PDEs-Essayan">{{cite journal |vauthors=Essayan DM |title=Cyclic nucleotide phosphodiesterases |journal=The Journal of Allergy and Clinical Immunology |volume=108 |issue=5 |pages=671–80 |year=2001 |pmid=11692087 |doi=10.1067/mai.2001.119555 }}</ref> which raises intracellular [[Cyclic adenosine monophosphate|cAMP]], activates [[cAMP-dependent protein kinase|PKA]], [[TNF inhibitor|inhibits TNF]]<ref name="PTX-Deree">{{cite journal |vauthors=Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R |title=Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition |journal=Clinics |volume=63 |issue=3 |pages=321–8 |year=2008 |pmid=18568240 |pmc=2664230 |doi=10.1590/S1807-59322008000300006 }}</ref><ref name="pmid9927365">{{cite journal |vauthors=Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U |title=Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages |journal=American Journal of Respiratory and Critical Care Medicine |volume=159 |issue=2 |pages=508–11 |year=1999 |pmid=9927365 |doi=10.1164/ajrccm.159.2.9804085 }}</ref> and [[leukotriene]] <ref name="LT-Peters-Golden">{{cite journal |vauthors=Peters-Golden M, Canetti C, Mancuso P, Coffey MJ |title=Leukotrienes: underappreciated mediators of innate immune responses |journal=Journal of Immunology |volume=174 |issue=2 |pages=589–94 |year=2005 |pmid=15634873 |doi=10.4049/jimmunol.174.2.589 }}</ref> synthesis, and [[Anti-inflammatory|reduces inflammation]] and [[innate immunity]].<ref name="LT-Peters-Golden"/> In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.<ref>{{cite journal |vauthors=Ward A, Clissold SP |title=Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy |journal=Drugs |volume=34 |issue=1 |pages=50–97 |year=1987 |pmid=3308412 |doi=10.2165/00003495-198734010-00003 }}</ref> Pentoxifylline is also an antagonist at [[adenosine]] 2 receptors.<ref name="pmid18220696">{{cite journal |vauthors=Rodríguez-Morán M, Guerrero-Romero F |title=Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes |journal=Current Diabetes Reviews |volume=4 |issue=1 |pages=55–62 |year=2008 |pmid=18220696 |doi=10.2174/157339908783502343 }}</ref>

==Effect on seizure==
In a study, the effect of pentoxifylline as a phosphodiestrase inhibitor was study on the pentylenetetrazol-induced seziure in the wild-type mice. Pentoxifylline in that study reduced the anti-convulsive effect of H-89 and reduced the seizure threshold.<ref>{{cite journal |vauthors=Hosseini-Zare MS, Salehi F, Seyedi SY, Azami K, Ghadiri T, Mobasseri M, Gholizadeh S, Beyer C, Sharifzadeh M |title=Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice |journal=European Journal of Pharmacology |volume=670 |issue=2–3 |pages=464–70 |year=2011 |pmid=21946102 |doi=10.1016/j.ejphar.2011.09.026 }}</ref>

==Research==
There is some evidence that pentoxifyllinenon can lower the levels of some [[biomarkers]] in non-alcoholic [[steatohepatitis]] but evidence is insufficient to determine if the drug is safe and effective for this use.<ref>{{cite journal |vauthors=Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S |title=Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease |journal=Lipids in Health and Disease |volume=10 |issue= |pages=49 |year=2011 |pmid=21477300 |pmc=3088890 |doi=10.1186/1476-511X-10-49 }}</ref>  Animal studies have been conducted exploring the use of pentoxifylline for [[erectile dysfunction]] and also human studies on [[Peyronie's disease]].<ref>{{cite journal | pmid=26579268| pmc=4149188| year=2011| author1=El-Sakka| first1=A. I.| title=Reversion of penile fibrosis: Current information and a new horizon| journal=Arab Journal of Urology| volume=9| issue=1| pages=49–55| doi=10.1016/j.aju.2011.03.013}}</ref><ref>{{cite journal | pmid=25392014| pmc=4430197| year=2015| author1=Anele| first1=U. A.| title=Molecular pathophysiology of priapism: Emerging targets| journal=Current drug targets| volume=16| issue=5| pages=474–83| last2=Morrison| first2=B. F.| last3=Burnett| first3=A. L.}}</ref>

==See also==
* [[Lisofylline]], an active metabolite of pentoxifylline
*[[Propentofylline]]

== References ==
{{reflist|2}}

== External links ==
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a685027.html Pentoxifylline MedlinePlus Drug Information]

{{Peripheral vasodilators}}
{{Phosphodiesterase inhibitors}}
{{Purinergics}}

[[Category:Adenosine receptor antagonists]]
[[Category:Adenosine reuptake inhibitors]]
[[Category:Ketones]]
[[Category:PDE4 inhibitors]]
[[Category:Vasodilators]]
[[Category:Xanthines]]